Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Oxaliplatin in Treating Patients With Recurrent or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Has Not Responded to Platinum- Based Chemotherapy

20 juni 2013 bijgewerkt door: Gynecologic Oncology Group

Phase II Evaluation of Oxaliplatin in Recurrent, Platinum Resistant and Refractory Ovarian Cancer

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: Phase II trial to study the effectiveness of oxaliplatin in treating patients who have recurrent or refractory ovarian epithelial cancer or primary peritoneal cancer that has not responded to platinum-based chemotherapy.

Studie Overzicht

Toestand

Voltooid

Conditie

Interventie / Behandeling

Geneesmiddel: oxaliplatine

Gedetailleerde beschrijving

OBJECTIVES: I. Determine the antitumor activity of oxaliplatin by measuring response rate in patients with recurrent or refractory, platinum resistant ovarian epithelial or primary peritoneal carcinoma who have failed on higher priority treatment protocols. II. Determine the nature and degree of toxicity of this drug in this patient population.

OUTLINE: Patients receive oxaliplatin IV over 2 hours. Treatment continues every 21 days for a maximum of 9 courses in the absence of unacceptable toxicity or disease progression. Patients are followed every 3 months for 2 years and then every 6 months for 3 years.

PROJECTED ACCRUAL: A total of 22-60 patients will be accrued for this study within 12-14 months.

Studietype

Ingrijpend

Fase

Fase 2

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

Canada
- Ontario
  - Kingston, Ontario, Canada, K7L 3N6
    - NCIC-Clinical Trials Group
Verenigde Staten
- Alabama
  - Birmingham, Alabama, Verenigde Staten, 35294
    - University of Alabama Comprehensive Cancer Center
- Arizona
  - Phoenix, Arizona, Verenigde Staten, 85006-2726
    - CCOP - Greater Phoenix
- California
  - Los Angeles, California, Verenigde Staten, 90033-0800
    - USC/Norris Comprehensive Cancer Center
  - Los Angeles, California, Verenigde Staten, 90095-1781
    - Jonsson Comprehensive Cancer Center, UCLA
  - Orange, California, Verenigde Staten, 92868
    - Chao Family Comprehensive Cancer Center
  - Palo Alto, California, Verenigde Staten, 94304
    - Women's Cancer Center
- Colorado
  - Denver, Colorado, Verenigde Staten, 80262
    - University of Colorado Cancer Center
- District of Columbia
  - Washington, District of Columbia, Verenigde Staten, 20307-5000
    - Walter Reed Army Medical Center
  - Washington, District of Columbia, Verenigde Staten, 20007
    - Vincent T. Lombardi Cancer Research Center, Georgetown University
- Florida
  - Tampa, Florida, Verenigde Staten, 33612
    - H. Lee Moffitt Cancer Center and Research Institute
- Georgia
  - Atlanta, Georgia, Verenigde Staten, 30322
    - Emory University Hospital - Atlanta
- Hawaii
  - Honolulu, Hawaii, Verenigde Staten, 96813
    - MBCCOP - Hawaii
- Illinois
  - Chicago, Illinois, Verenigde Staten, 60612-7323
    - MBCCOP - University of Illinois at Chicago
  - Chicago, Illinois, Verenigde Staten, 60612
    - Rush-Presbyterian-St. Luke's Medical Center
  - Chicago, Illinois, Verenigde Staten, 60637
    - University of Chicago Cancer Research Center
  - Evanston, Illinois, Verenigde Staten, 60201
    - CCOP - Evanston
  - Springfield, Illinois, Verenigde Staten, 62526
    - CCOP - Central Illinois
- Indiana
  - Indianapolis, Indiana, Verenigde Staten, 46202-5265
    - Indiana University Cancer Center
- Iowa
  - Des Moines, Iowa, Verenigde Staten, 10309-1016
    - CCOP - Iowa Oncology Research Association
  - Iowa City, Iowa, Verenigde Staten, 52242
    - University of Iowa Hospitals and Clinics
- Kentucky
  - Lexington, Kentucky, Verenigde Staten, 40536-0084
    - Albert B. Chandler Medical Center, University of Kentucky
- Maryland
  - Baltimore, Maryland, Verenigde Staten, 21287
    - Johns Hopkins Oncology Center
  - Bethesda, Maryland, Verenigde Staten, 20892
    - Radiation Oncology Branch
  - Bethesda, Maryland, Verenigde Staten, 20892
    - Medicine Branch
- Massachusetts
  - Boston, Massachusetts, Verenigde Staten, 02111
    - Tufts University School of Medicine
  - Worcester, Massachusetts, Verenigde Staten, 01655
    - University of Massachusetts Memorial Medical Center
- Michigan
  - Ann Arbor, Michigan, Verenigde Staten, 48106
    - CCOP - Ann Arbor Regional
  - Detroit, Michigan, Verenigde Staten, 48201
    - Barbara Ann Karmanos Cancer Institute
- Minnesota
  - Minneapolis, Minnesota, Verenigde Staten, 55455
    - University of Minnesota Cancer Center
- Mississippi
  - Jackson, Mississippi, Verenigde Staten, 39216-4505
    - University of Mississippi Medical Center
  - Keesler AFB, Mississippi, Verenigde Staten, 39534-2576
    - Keesler Medical Center - Keesler AFB
- Missouri
  - Columbia, Missouri, Verenigde Staten, 65203
    - Ellis Fischel Cancer Center
  - Kansas City, Missouri, Verenigde Staten, 64131
    - CCOP - Kansas City
  - Saint Louis, Missouri, Verenigde Staten, 63110
    - Washington University School of Medicine
  - Springfield, Missouri, Verenigde Staten, 65807
    - CCOP - Cancer Research for the Ozarks
- Montana
  - Billings, Montana, Verenigde Staten, 59101
    - CCOP - Montana Cancer Consortium
- Nebraska
  - Omaha, Nebraska, Verenigde Staten, 68131
    - CCOP - Missouri Valley Cancer Consortium
- Nevada
  - Las Vegas, Nevada, Verenigde Staten, 89106
    - CCOP - Southern Nevada Cancer Research Foundation
- New Jersey
  - Camden, New Jersey, Verenigde Staten, 08103
    - Cooper Hospital/University Medical Center
- New York
  - Albany, New York, Verenigde Staten, 12208
    - Cancer Center of Albany Medical Center
  - Brooklyn, New York, Verenigde Staten, 11203
    - State University of New York Health Science Center at Brooklyn
  - Manhasset, New York, Verenigde Staten, 11030
    - North Shore University Hospital
  - New York, New York, Verenigde Staten, 10021
    - Memorial Sloan-Kettering Cancer Center
  - Rochester, New York, Verenigde Staten, 14642
    - University of Rochester Cancer Center
  - Stony Brook, New York, Verenigde Staten, 11790-9832
    - State University of New York Health Sciences Center - Stony Brook
- North Carolina
  - Chapel Hill, North Carolina, Verenigde Staten, 27599-7295
    - Lineberger Comprehensive Cancer Center, UNC
  - Durham, North Carolina, Verenigde Staten, 27710
    - Duke Comprehensive Cancer Center
  - Winston-Salem, North Carolina, Verenigde Staten, 27157-1082
    - Comprehensive Cancer Center of Wake Forest University Baptist Medical Center
  - Winston-Salem, North Carolina, Verenigde Staten, 27103
    - Brookview Research, Inc.
- Ohio
  - Cincinnati, Ohio, Verenigde Staten, 45219
    - Barrett Cancer Center, The University Hospital
  - Cleveland, Ohio, Verenigde Staten, 44195
    - Cleveland Clinic Cancer Center
  - Cleveland, Ohio, Verenigde Staten, 44106-5065
    - Ireland Cancer Center
  - Columbus, Ohio, Verenigde Staten, 43210
    - Arthur G. James Cancer Hospital - Ohio State University
- Oklahoma
  - Oklahoma City, Oklahoma, Verenigde Staten, 73190
    - University of Oklahoma College of Medicine
  - Tulsa, Oklahoma, Verenigde Staten, 74136
    - CCOP - St. Francis Hospital/Natalie Warren Bryant Cancer Center
- Oregon
  - Portland, Oregon, Verenigde Staten, 97213
    - CCOP - Columbia River Program
- Pennsylvania
  - Abington, Pennsylvania, Verenigde Staten, 19001
    - Abington Memorial Hospital
  - Hershey, Pennsylvania, Verenigde Staten, 17033
    - Milton S. Hershey Medical Center
  - Philadelphia, Pennsylvania, Verenigde Staten, 19111
    - Fox Chase Cancer Center
  - Philadelphia, Pennsylvania, Verenigde Staten, 19107
    - Pennsylvania Hospital
  - Philadelphia, Pennsylvania, Verenigde Staten, 19104
    - University of Pennsylvania Cancer Center
  - Philadelphia, Pennsylvania, Verenigde Staten, 19107
    - Kimmel Cancer Center of Thomas Jefferson University - Philadelphia
  - Wynnewood, Pennsylvania, Verenigde Staten, 19096
    - CCOP - MainLine Health
- South Carolina
  - Charleston, South Carolina, Verenigde Staten, 29425-0721
    - Medical University of South Carolina
  - Greenville, South Carolina, Verenigde Staten, 29615
    - CCOP - Greenville
  - Spartanburg, South Carolina, Verenigde Staten, 29303
    - CCOP - Upstate Carolina
- Tennessee
  - Memphis, Tennessee, Verenigde Staten, 38117
    - CCOP - Baptist Cancer Institute
- Texas
  - Dallas, Texas, Verenigde Staten, 75235-9154
    - Simmons Cancer Center - Dallas
  - Houston, Texas, Verenigde Staten, 77030
    - University of Texas - MD Anderson Cancer Center
  - Temple, Texas, Verenigde Staten, 76508
    - CCOP - Scott and White Hospital
- Virginia
  - Charlottesville, Virginia, Verenigde Staten, 22908
    - Cancer Center, University of Virginia HSC
- Washington
  - Seattle, Washington, Verenigde Staten, 98195-6043
    - University of Washington Medical Center
  - Tacoma, Washington, Verenigde Staten, 98405
    - Tacoma General Hospital

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

Kind
Volwassen
Oudere volwassene

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Vrouw

Beschrijving

DISEASE CHARACTERISTICS: Histologically confirmed recurrent or refractory ovarian epithelial or primary peritoneal carcinoma Bidimensionally measurable disease Ascites and pleural effusions are not considered measurable disease Sonography acceptable provided lesions are clearly defined on initial examination and bidimensionally measurable Must have had 1 prior platinum based chemotherapy regimen containing carboplatin, cisplatin, or another organoplatinum compound for management of primary disease Initial treatment may include high dose therapy, consolidation, or extended therapy administered after surgical or nonsurgical assessment No additional cytotoxic chemotherapy for management of recurrent or persistent disease, including retreatment with initial chemotherapy regimens Must be considered platinum resistant or refractory Treatment free interval of less than 6 months following platinum or progression during platinum based therapy No known brain metastases Must not be eligible for a higher priority GOG protocol

PATIENT CHARACTERISTICS: Age: Not specified Performance status: GOG 0-2 Life expectancy: Not specified Hematopoietic: Absolute neutrophil count at least 1,500/mm3 Platelet count at least lower limit of normal Hepatic: Bilirubin no greater than 1.5 times upper limit of normal (ULN) SGOT no greater than 2.5 times ULN Alkaline phosphatase no greater than 2.5 times ULN Renal: Creatinine no greater than 1.5 times ULN Cardiovascular: No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia Other: Not pregnant or nursing Fertile patients must use effective contraception No active infection requiring antibiotics No evidence of preexisting peripheral sensory neuropathy greater than grade 1, including residual neuropathy attributed to prior chemotherapy and other chronic conditions (e.g., diabetes, venous stasis, and carpal tunnel syndrome) No history of allergy to platinum compounds or to antiemetics appropriate for administration in conjunction with protocol directed chemotherapy No other uncontrolled concurrent illness (e.g., ongoing or active infection) No other malignancy within the past 5 years except nonmelanoma skin cancer and no other prior malignancy whose prior cancer treatment contraindicates this protocol therapy

PRIOR CONCURRENT THERAPY: Biologic therapy: At least 3 weeks since prior biologic therapy At least 3 weeks since prior immunotherapy No concurrent colony stimulating factors (CSFs) during first course of therapy At least 24 hours since prior CSFs during subsequent courses of therapy Chemotherapy: See Disease Characteristics No prior oxaliplatin No more than 1 prior chemotherapy regimen If initial therapy did not include paclitaxel, a second regimen including paclitaxel is allowed At least 3 weeks since prior chemotherapy and recovered Endocrine therapy: At least 1 week since prior hormonal therapy directed at malignant tumor Concurrent continuation of hormone replacement therapy allowed Radiotherapy: At least 3 weeks since prior radiotherapy and recovered No prior radiotherapy to sites of measurable disease used on this trial No prior radiotherapy to greater than 25% of bone marrow Surgery: At least 3 weeks since prior surgery and recovered Other: No other concurrent investigational agents No concurrent antiretroviral therapy (HAART)

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

Primair doel: Behandeling

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

Gynecologic Oncology Group

Medewerkers

National Cancer Institute (NCI)

Onderzoekers

Studie stoel: Paula M. Fracasso, MD, PhD, Washington University Siteman Cancer Center

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start

1 februari 2000

Studie voltooiing (Werkelijk)

1 juli 2004

Studieregistratiedata

Eerst ingediend

2 juni 2000

Eerst ingediend dat voldeed aan de QC-criteria

28 april 2003

Eerst geplaatst (Schatting)

29 april 2003

Updates van studierecords

Laatste update geplaatst (Schatting)

21 juni 2013

Laatste update ingediend die voldeed aan QC-criteria

20 juni 2013

Laatst geverifieerd

1 maart 2003

Meer informatie

Termen gerelateerd aan deze studie

Trefwoorden

Aanvullende relevante MeSH-voorwaarden

Andere studie-ID-nummers

CDR0000067851
GOG-126K

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .